The sixth annual ASH State-of-the-Art Symposium (SAS) took place at the Palmer House Hilton in Chicago, IL, on September 12-13. With a sell-out crowd, 13 stimulating educational sessions led by expert speakers, and 11 commercial supporters and exhibitors, this meeting can truly be called a success.
If you missed the 2008 SAS, you can purchase both the Program Book and DVD of the meeting through the ASH Store. The Program Book contains the printed session slides from each presentation given. The DVD features audio synchronized to the slides of each of the presentations from this event. These educational products will be available for sale in October.
Sessions included:
Stem Cell Biology Unveiled
Hal E. Broxmeyer, PhD, Indiana University School of Medicine
Changes in the World Health Organization (WHO) Classification of Myeloid Malignancies
James W. Vardiman, MD, University of Chicago
Complement, Immunity, and Stem Cell Hypoplasia
Neal S. Young, MD, National Institutes of Health
The New Paradigm in MDS Management
Alan F. List, MD, H. Lee Moffitt Cancer Center
MPDs Come of Age
Ayalew Tefferi, MD, Mayo Clinic
CML after Imatinib
Jorge Cortes, MD, M. D. Anderson Cancer Center
Managing CLL by Prognostic Risk
Mark A. Weiss, MD, Memorial Sloan-Kettering Cancer Center
Discriminating Outcome and Treatment Strategies for AML
Martin S. Tallman, MD, Northwestern University
Myeloma Stem Cell Transplant: If, When, and Why?
Sagar Lonial, MD, Winship Cancer Institute
The New Standards for Myeloma Medical Management
Irene Ghobrial, MD, Dana-Farber Cancer Institute
Update on Treatment Options for Follicular Lymphoma
Stephanie A. Gregory, MD, Rush University Medical Center
Novel Approaches for the Treatment of Mantle-Cell Lymphoma
Brad Kahl, MD, University of Wisconsin
Hodgkin Lymphoma: Streamlining Therapy Based on Stage and Risk Factors
Joseph M. Connors, MD, British Columbia Cancer Agency
The American Society of Hematology would like to thank the following SAS commercial supporters and exhibitors:
| Lead Commercial Supporters: | Amgen Inc. Celgene Corporation Cephalon Oncology Genentech BioOncology Novartis Oncology |
| General Commercial Supporters: | Lilly Oncology Millennium – The Takeda Oncology Company |
| Exhibitors: | Alexion Pharmaceuticals, Inc. Biogen Idec Eisai, Inc. Vion Pharmaceuticals, Inc. |